Cambridge Healthtech Institute’s 4th Annual
Improving Immunotherapy Efficacy and Safety
Developing Targeted, Safe Immunotherapies
April 8-9, 2019
Immunotherapies represent a step-change in cancer treatment, yet questions still remain around their efficacy, targeting and toxicity. Cambridge Healthtech Institute’s Improving Immunotherapy Efficacy and Safety conference details the latest developments in immunotherapy, including established and emerging targets and modalities, new engineering strategies, combinations, biomarkers, effective preclinical models and strategies to mitigate toxicity and recent clinical developments. Examples will come from the world of checkpoint inhibitors, adoptive T cell therapy, combinations and oncolytic viruses. We will also investigate manipulating the tumor microenvironment and emerging IO targets.
ADVANCES IN CHECKPOINTS
PD-1 Antibodies Are Transforming Cancer Treatment Both as Mono and Combination Therapy
Roy Baynes, MD, PhD., Senior Vice President, Global Clinical Development & CMO, Merck Research Labs
Best-In-Class PD-1 Pathway Blockade with Efficacy Against Cold Tumors
Michael Curran, PhD., Assistant Professor, Department of Immunology, MD Anderson Cancer Centre
Third-Generation Immune Checkpoint Inhibitors and Development of AB154, A Clinical-Stage TIGIT Antibody
Juan C. Jaen, PhD., President, Arcus Biosciences, Inc.
Immunotherapy for Cancer: The Need for More Effective Combination Therapies
Ronald Herbst, PhD, Vice President, R&D and Head, Oncology Research, MedImmune
Evolutionary Dynamics of the Immune Response to Cancer: Implications for Immunotherapy
Brad Nelson, PhD, Co-Director, Immunotherapy Program, BC Cancer Agency
NK cells: Growing up to Become Safe and Efficacious Cellular Therapeutics?
Hans Klingemann, MD, PhD, VP, Research and Development, NantKwest Inc.
Reprogramming Human T Cell Function and Specificity with Non-Viral Genome Targeting
Theodore Roth, PhD., Student, Marson Laboratory, UCSF
Controllable CAR T Cell Therapy
Travis Young, PhD., VP, Biologics, CALIBR
Novel Strategies to Mitigate Toxicities After Chimeric Antigen Receptor T Cell Therapy
Saad J. Kenderian, Assistant Professor, Medicine and Oncology, Mayo Clinic College of Medicine
Presentation to be Announced
Luncheon Presentation: Target Specificity Screening of CAR T Cells Using Human Cell Microarray Technology
Alex Kelly, US Business Development Manager, Retrogenix Limited
* The program is subject to change without notice, due to unforeseen reason.